A Single Institution Respective Study of Tyrosine Kinase Inhibitor Cessation in Patients with Chronic Phase CML in MMR
James McCloskey(Hackensack University Medical Center), Stefan Faderl(Jazz Pharmaceuticals (United States)), Jamie Koprivnikar(Hackensack University Medical Center), Genique Stanislaus(Hackensack University Medical Center), Christina Howlett(Rutgers, The State University of New Jersey), Stuart L. Goldberg(Hackensack University Medical Center), Themba Nyirenda(Hackensack University Medical Center)
Cited by 3
Related Papers
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
|Cancer|2006|607
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
|Blood|2006|468
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
|The Lancet Oncology|2012|411